Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-004 Phase 1 in Healthy Volunteers
NCT06236009Phase 1Completed
- Sponsor
- Takeda
- Start
- Nov 2024
- Primary completion
- Oct 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TAK-004 (3 arms), sponsored by Takeda. Primary endpoint: Adverse Events at 60 days. Started Nov 2024; status: completed.
02
Drugs
TAK-004
Beyond the preview
Go deeper on NCT06236009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06236009.